Stochastic modelling of the role of cisplatin in altered fractionation schedules for head and neck cancer

Physica Medica

Volumn 26, Issue 4, 2010, Pages 177-183

  Marcu, Loredana ^a,b   Bezak, Eva ^a,c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF ORADEA   (Romania)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Altered fractionation; Chemotherapy; Modelling; Monte carlo

Indexed keywords

CISPLATIN;

ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DISEASE MODEL; HEAD AND NECK CANCER; IN VIVO STUDY; MATHEMATICAL ANALYSIS; MONTE CARLO METHOD; PROBABILITY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; STOCHASTIC MODEL; TREATMENT OUTCOME;

CELL CYCLE; CELL PROLIFERATION; CISPLATIN; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HEAD AND NECK NEOPLASMS; HUMANS; KINETICS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PROBABILITY; STOCHASTIC PROCESSES; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 77956873729     PISSN: 11201797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejmp.2009.11.004     Document Type: Article

References (20)

1. Trott K.R. Cell repopulation and overall treatment time. Int J Radiat Oncol Biol Phys 1990, 19:1071-1075.
2. Fu K., Pajak T., Trotti A., Jones CU., Spence S.A., Phillips T., et al. Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000, 48:7-16.
3. Jeremic B., Shibamoto Y., Stanisavljevic B., Milojevic L., Milicic B., Nikolic N., et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol 1997, 43:29-37.
4. Reed E., Kohn K.W. Platinum analogues. Cancer chemotherapy-principles and practice 1990, Lippincott, Philadelphia. B. Chabner, J.M. Collins (Eds.).
5. Sorenson C.M., Barry M.A., Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990, 82:749-754.
6. Cisplatin - chemistry and biochemistry of a leading anticancer drug 1999, Wiley-VCH, Zürich. B. Lippert (Ed.).
7. Lawrence T.S., Blackstock A.W., McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 2003, 13:13-21.
8. Dewit L. Combined treatment of radiation and cis-diamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 1987, 13:403-426.
9. Nakamoto S., Mitsuhashi N., Takahashi T., Sakurai H., Niibe H. An interaction of cisplatin and radiation in two rat yolk sac tumour cell lines with different radiosensitivities in vitro. Int J Radiat Biol 1996, 70:747-753.
10. Marcu L., Bezak E., Olver I. Scheduling cisplatin and radiotherapy in the treatment of squamous cell carcinomas of the head and neck: a modelling approach. Phys Med Biol 2006, 51:3625-3637.
11. Marcu L., van Doorn T., Zavgorodni S., Olver I. Growth of a virtual tumour using probabilistic methods of cell generation. Australas Phys Eng Sci Med 2002, 25:155-161.
12. Begg A.C. Cell proliferation in tumours. Basic clinical radiobiology 1997, 14-23. Oxford University Press, New York. 2nd ed. G.G. Steel (Ed.).
13. Steel G.G. The growth rate of tumours. Basic clinical radiobiology 1997, 8-13. Oxford University Press, New York. 2nd ed. G.G. Steel (Ed.).
14. Tannock I.F., Hill R.P. The basic science of oncology 1992, McGraw-Hill, pp. 155-176. 2nd ed.
15. Hall E. Radiobiology for the radiologist 2000, Lippincott Williams & Wilkins. 5th ed.
16. Tubiana M. The growth and progression of human tumours: implications for management strategy. Radiother Oncol 1986, 6:167-184.
17. Bourhis J., Overgaard J., Audry H., Ang K., Saunders M., Bernier J., et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006, 368(9538):843-854.
18. Vivek R., Baludavid M., Mohanram R., Chitra, Amanullah, Vijayalakshmi, et al. Concurrent chemo-irradiation using accelerated concomitant boost radiation therapy in loco-regionally advanced head and neck squamous cell carcinomas. J Cancer Res Ther 2006, 2(3):90-96.
19. Beckmann G.K., Hoppe F., Pfreundner L., Flentje M.P. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck 2005, 27(1):36-43.
20. Garden A.S., Harris J., Trotti A., Jones C.U., Carrascosa L., Cheng J.D., et al. Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiat Oncol Biol Phys 2008, 71(5). p. 1351-1355.